222 related articles for article (PubMed ID: 21864888)
21. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma.
Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
Gynecol Oncol; 1999 Sep; 74(3):385-94. PubMed ID: 10479498
[TBL] [Abstract][Full Text] [Related]
22. Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion.
Orezzoli JP; Sioletic S; Olawaiye A; Oliva E; del Carmen MG
Gynecol Oncol; 2009 Jun; 113(3):316-23. PubMed ID: 19345400
[TBL] [Abstract][Full Text] [Related]
23. [Expression of P53, P63, and C-erbB-2 in endometrioid adenocarcinoma and their clinicopathological significance].
Hu WF; Liu MQ; Zhao Q
Ai Zheng; 2004 Sep; 23(9):1021-5. PubMed ID: 15363194
[TBL] [Abstract][Full Text] [Related]
24. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
[TBL] [Abstract][Full Text] [Related]
25. Role of bcl-2 in endometrioid corpus cancer: an experimental study.
Mariani A; Sebo TJ; Cliby WA; Keeney GL; Riehle DL; Lesnick TG; Podratz KC
Anticancer Res; 2006; 26(2A):823-7. PubMed ID: 16619475
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
Suthipintawong C; Wejaranayang C; Vipupinyo C
J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
[TBL] [Abstract][Full Text] [Related]
28. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
[TBL] [Abstract][Full Text] [Related]
29. Expression of estrogen receptors alpha and beta, and progesterone receptors A and B in human mucinous carcinoma of the endometrium.
Shabani N; Mylonas I; Jeschke U; Thaqi A; Kuhn C; Puchner T; Friese K
Anticancer Res; 2007; 27(4A):2027-33. PubMed ID: 17649817
[TBL] [Abstract][Full Text] [Related]
30. Uterine papillary serous carcinoma (pure and mixed type) compared with moderately and poorly differentiated endometrioid carcinoma. A clinicopathologic study.
Halperin R; Zehavi S; Langer R; Hadas E; Bukovsky I; Schneider D
Eur J Gynaecol Oncol; 2002; 23(4):300-4. PubMed ID: 12214728
[TBL] [Abstract][Full Text] [Related]
31. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma.
Oreskovic S; Babic D; Kalafatic D; Barisic D; Beketic-Oreskovic L
Gynecol Oncol; 2004 Apr; 93(1):34-40. PubMed ID: 15047211
[TBL] [Abstract][Full Text] [Related]
32. Tumors of the uterine isthmus: clinicopathologic features and immunohistochemical characterization of p53 expression and hormone receptors.
Jacques SM; Qureshi F; Ramirez NC; Malviya VK; Lawrence WD
Int J Gynecol Pathol; 1997 Jan; 16(1):38-44. PubMed ID: 8986531
[TBL] [Abstract][Full Text] [Related]
33. Progesterone receptor isoforms as a prognostic marker in human endometrial carcinoma.
Saito S; Ito K; Nagase S; Suzuki T; Akahira J; Okamura K; Yaegashi N; Sasano H
Cancer Sci; 2006 Dec; 97(12):1308-14. PubMed ID: 16999816
[TBL] [Abstract][Full Text] [Related]
34. Analysis of potential prognostic factors in 111 patients with ovarian cancer.
Hornung R; Urs E; Serenella E; Edward W; Ursula S; Urs H; Daniel F
Cancer Lett; 2004 Mar; 206(1):97-106. PubMed ID: 15019165
[TBL] [Abstract][Full Text] [Related]
35. [Clinical characteristics and prognosis of breast cancer patients with vascular invasion].
Zhao WH; Xu BH; Zhang P; Li Q; Zhao LM; Sun Y
Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):137-40. PubMed ID: 17645853
[TBL] [Abstract][Full Text] [Related]
36. Endometrial cancer in women 40 years old or younger.
Duska LR; Garrett A; Rueda BR; Haas J; Chang Y; Fuller AF
Gynecol Oncol; 2001 Nov; 83(2):388-93. PubMed ID: 11606102
[TBL] [Abstract][Full Text] [Related]
37. Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma.
Vaidya AP; Horowitz NS; Oliva E; Halpern EF; Duska LR
Gynecol Oncol; 2006 Nov; 103(2):684-7. PubMed ID: 16797683
[TBL] [Abstract][Full Text] [Related]
38. 14-3-3sigma in endometrial cancer--a possible prognostic marker in early-stage cancer.
Ito K; Suzuki T; Akahira J; Sakuma M; Saitou S; Okamoto S; Niikura H; Okamura K; Yaegashi N; Sasano H; Inoue S
Clin Cancer Res; 2005 Oct; 11(20):7384-91. PubMed ID: 16243811
[TBL] [Abstract][Full Text] [Related]
39. The use of P53, PTEN, and C-erbB-2 to differentiate uterine serous papillary carcinoma from endometrioid endometrial carcinoma.
Macwhinnie N; Monaghan H
Int J Gynecol Cancer; 2004; 14(5):938-46. PubMed ID: 15361207
[TBL] [Abstract][Full Text] [Related]
40. p53, estrogen and progesterone receptors in diagnostic curettage for endometrial adenocarcinoma and their correlation with morphological data and disease stage at hysterectomy.
Bonfitto VL; de Angelo Andrade LA
Sao Paulo Med J; 2003 Jul; 121(4):163-6. PubMed ID: 14595509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]